AI traction, strategic mergers, and fresh capital drive market buzz

*together with Stock Market Media & Brownstone Research

Good day, 360!

Here are some of our top movers today. And don’t forget to join us at 12pm EST today for a one-month check in with Steve Strazza over in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

GPUS - Up over 40% in the pre-market after announcing subsidiary as ROI surpasses 160,000 app downloads on Apple App Store and Google Play

JFBR - Up over 36% in pre after announcing it has along with Impact Acquisitions received approval from TSX Venture Exchange for Fort Products’ merger at a valuation of up to approximately $15 Million

PCSA - Up over 30% in pre after announces pricing of $7 Million public offering

HOTLIST🔥

GPUS - Up over 40% in the pre-market after announcing subsidiary askROI surpasses 160,000 app downloads on Apple App Store and Google Play

Hyperscale Data, Inc. (GPUS) through its subsidiaries, owns and/or operates data centers at which it mines Bitcoin in North America, Europe, the Middle East, and internationally.

Yesterday, the company announced that its wholly owned indirect subsidiary askROI, Inc. (“askROI”), has surpassed 160,000 cumulative app downloads between the Apple App Store and Google Play. This marks a key milestone in askROI’s early growth and adoption.

askROI recently announced the launch of its app in both the Apple App Store and Google Play, offering users access to advanced artificial intelligence (“AI”) tools for both personal and business applications. Despite minimal marketing efforts to date, askROI’s organic traction continues to grow as askROI seeks to fine-tune its AI platform.

Shares of GPUS traded up over 40% in the pre-market in reaction to the news.

The $2.20 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.40, $2.60, $2.80, $3 and then the pre-market high at $3.16. Beyond that, $4 and $5 come into play.

Below $2.20, targets to the downside are $2, $1.80 and then a gap fill at $1.69.

JFBR - Up over 36% in pre after announcing it has along with Impact Acquisitions received approval from TSX Venture Exchange for Fort Products’ merger at a valuation of up to Approximately $15 Million

Jeffs' Brands Ltd (JFBR) is a data-driven e-commerce company operating on the Amazon Marketplace. 

In the pre-market this morning, the company announced that the TSX Venture Exchange has approved the previously announced acquisition by Impact Acquisitions Corp. (TSXV: IMPC.P) of 100% of the equity interests of Fort Products Limited (“Fort”), a wholly-owned U.K.-based subsidiary of Jeffs’ Brands, in exchange for an initial 75.02%, and up to an 83.29% contingent upon meeting predetermined milestones. 

Upon completion of the Proposed Transaction, Impact will issue 100,000,000 common shares to the Company at a deemed price per share of CAD $0.171246 for deemed aggregate consideration of approximately CAD$17.1 million (approximately US$12.5 million). 

Based an independent valuation report by Evans & Evans dated April 14, 2025, with respect to the fair market value of Fort as of January 31, 2025 (the “Valuation Report”), the fair market of Fort ranges between CAD$16.86 million to CAD$20.59 million (approximately US$12.5-$15 million), on a controlling, marketable basis, subject to the assumptions and qualifications specified therein.

According to Finviz, JFBR had a market capitalization of just $3.59 million based on yesterday’s close.

Shares of JFBR traded up over 36% in the pre-market in reaction to the announcement.

The $8.10 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $8.75, $9 and then the pre-market high at $9.61. Beyond that, $10.71 and $12.50 come into play.

Below $8.10, targets to the downside are $7.80, $7.60, $7 and then a gap fill at $6.50.

PCSA - Up over 30% in pre after announces pricing of $7 Million public offering 

Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies.

On Wednesday, the company announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. 

The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. The closing of the offering is expected to occur on or about June 18, 2025, subject to the satisfaction of customary closing conditions.

Shares of PCSA traded up over 30% in the pre-market in reaction to the news.

The $0.2850 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.3250, $0.35, $0.40 and then the pre-market high at $0.5507 with $0.70 above that.

Below $0.2850, targets to the downside are $0.25, a gap fill at $0.2420 and then $0.20 below that.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed past the MOON 🌝.  Simply text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.